Single-Domain Antibody-Based TCR-Like CAR-T: A Potential Cancer Therapy

Area of Science:

• Immunotherapy
• Oncology
• Cellular Engineering

Background:

• CAR-T cell therapy shows success against extracellular antigens, notably CD19 CAR-T for hematological malignancies.
• Targeting intracellular antigens with CAR-T cells (TCR-like CAR-T) remains a significant challenge.
• The rarity of TCR-like CAR-T therapies is attributed to current limitations in targeting intracellular tumor antigens.

Purpose of the Study:

• To review and propose optimized strategies for enhancing TCR-like CAR-T cell reprogramming.
• To discuss the potential of single-domain antibodies as an alternative to scFvs in CAR-T therapy.
• To highlight advancements for CAR-T immunotherapies targeting intracellular antigens.

Main Methods:

• Literature review of current CAR-T therapy approaches.
• Analysis of limitations in targeting intracellular antigens.
• Exploration of single-domain antibodies as novel CAR components.

Main Results:

• Identified limitations in current TCR-like CAR-T therapy.
• Proposed optimized initiatives for improving TCR-like CAR-T reprogramming.
• Highlighted the potential of single-domain antibodies for intracellular antigen targeting.

Conclusions:

• TCR-like CAR-T therapies face challenges in targeting intracellular antigens.
• Single-domain antibodies offer a promising alternative to conventional scFvs for CAR-T development.
• Optimized strategies and novel antibody formats are crucial for advancing CAR-T immunotherapies against intracellular targets.